Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 13/20 | 0.77 |
| ▸ | ESR1 | P03372 | 13/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.77 |
| ▸ | TOP1 | P11387 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125320 | 0.89 | HRAS (0.83) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL14002814 | 0.87 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| Stallimycin SCHEMBL108585 | 0.87 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| Stallimycin SCHEMBL193003 | 0.86 | KDM4E (1.00) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7123738 | 0.85 | HRAS (0.77) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7127894 | 0.84 | HRAS (0.69) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5745871 | 0.83 | TOP1 (0.62) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5749627 | 0.83 | TOP1 (0.62) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL6497712 | 0.83 | KDM4E (0.59) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL13117928 | 0.83 | TOP1 (0.57) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951951-B2 | Process for preparing distamycin derivatives | PHARMACIA ITALIA S.P.A. (IT) | 2005-10-04 | — | — | US | disclosed |
| US-20040082759-A1 | Process for preparing distamycin derivatives | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| EP-1324983-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | Pharmacia Italia S.p.A. (IT) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002002523-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | PHARMACIA ITALIA S.P.A. (IT) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082759-A1 | Process for preparing distamycin derivatives | GSTP1, GSTA1, GSS | HRAS 15/4885ESR1 4086/4885ESR2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.